TP53 and ovarian carcinoma: Similar effects were observed in cell lines harboring different mut-p53 variants, from breast (MD-MB-468/p53R273H, SK-BR-3/p53R175H, and SUM-159PT/p53R158insS) (Fig. 1b), prostate, colon, liver, and ovarian cancer (DU 145/p53P223L,V274F, HT-29/p53R273H, Mahlavu/p53R249S, TOV-112D/p53R175H, Supplementary Fig. 1b).